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PL1 - Preventive, predictive and 
personalized medicine - where are 
we?
PL1 - 1
European strategies, new guidelines & 
standardisation in predictive, preventive & 
personalised medicine
Golubnitschaja Olga
European Association for Predictive, Preventive and 
Personalised Medicine, EPMA, Radiological Clinic, Friedrich-
Wilhelms-University of Bonn, Bonn, Germany
Corresponding author: olga .golubnitschaja@ukb .uni-bonn .de
Predictive, preventive & personalised medicine is 
a new strategy in healthcare aiming at application 
of innovative biotechnologies in the prediction of 
human pathologies, the development of timely 
prevention and individualised therapy-planning . 
Predictive diagnostics is considered as a reliable 
navigation system for targeted preventive meas-
ures and consequent development of treatment 
approaches tailored to the patient . Of paramount 
importance is communication among profession-
als – medical doctors, biotechnologists, comput-
er-scientists, healthcare providers, policy-makers, 
educators, who are obligatorily involved in the 
paradigm change from delayed interventional to 
predictive medicine . This concept is considered as 
medicine of future . New strategies which EPMA 
represents for further consideration at the EU-
Commission, the European Parliament, WHO and 
UNO are elaborated by the consortium of the 
world-leading professionals (Europe-unrestrict-
ed) . The EPMA Mission and Objectives in the field 
of Predictive, Preventive & Personalized Medicine 
(PPPM) have been introduced to the Organisation 
of United Nations . The participants of the meet-
ing agreed that the paradigm change can be 
achieved only by coordinated measures well-fo-
cused on solving the accumulating problems in 
healthcare and the concomitant economical bur-
den that societies across the globe are facing 
more and more .
PL1 - 2
Recent technology towards predictive, 
preventive and personalized medicine
Ferrari Maurizio
Vita-Salute San Raffaele University, San Raffaele Scientific 
Institute, Genomic Unit for the Diagnosis of Human Pathologies, 
Center for Translational Genomics and Bioinformatics, Milano, 
Italy
Corresponding author: ferrari .maurizio@hsr .it
Personalized medicine, which simply means selec-
tion of treatment best suited for an individual, in-
volves integration and translation of several new 
technologies in clinical care of patients . 
Researchers have discovered hundreds of genes 
that harbour variations contributing to human ill-
ness, identified genetic variability in patients’ re-
sponses to dozens of treatments, and begun to 
target the molecular causes of some diseases . In 
addition, scientists are developing and using diag-
nostic tests based on genetics or other molecular 
mechanisms to better predict patients’ responses 
to targeted therapy . 
Advances in DNA analysis to develop methods, 
which are increasingly specific, sensitive, fast, sim-
ple, automatable, and cost-effective, are consid-
ered paramount . These demands are currently 
driving the rapid evolution of a diverse range of 
newer technologies . 
For the future of genomics is demanding the rapid 
evolution of miniaturization (nanotechnogy) and 
high-throughput genotyping technologies (next 
generation sequencing) toward increased speed 
and reduced cost .
The success of personalized medicine depends on 
having accurate diagnostic tests that identify pa-
tients who can benefit from targeted therapies . 
Within the past few years, a growing number of 
businesses have begun to offer direct to consumer 
genetic tests . These tests are designed to help in-
dividuals better understand their genetic predis-
position for a given health condition . 
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Another important step will be expanding efforts 
to develop tissue banks containing specimens 
along with information linking them to clinical 
outcomes . 
In this arena Laboratory Medicine should play a 
major role . 
PL2 - Laboratory medicine online
PL1 – 1
Health literacy on laboratory tests
Abstract not provided .
PL2 - 2
Mobile technology and laboratory 
information services
Soini Esa
Mylab Corp ., CEO, Tampere, Finland
Corresponding author: esa .soini@mylab .fi
Throughout the history there have been several 
successful technology breakthroughs that have 
had a global impact . The latest addition to these 
revolutionary technologies is the mobile commu-
nication . The wireless mobile technology sets us 
free from the limitations of time and space .
In principle mobile technology means methods 
and equipment that use electromagnetic signals 
for the wireless communication . The mobile tech-
nology is mainly based on radio waves invented 
by Guglielmo Marconi at the end of the 19th cen-
tury . Because electromagnetic spectrum is a scarce 
resource there is a need for very strict communica-
tion standards . We have the Global Positioning 
System (GPS) and its European versions for world-
wide accurate navigation . General wireless point-
to-point communication utilizes various digital 
cellular standards like GSM, GPRS, WCDMA, and 
LTE . The best method for mobile Internet usage is 
so called Wireless Local Area Network (WLAN) . Fi-
nally we have different technologies for very short 
distance communication like Bluetooth, RFID, and 
Near Field Communication (NFC) .
Internet and the above mentioned mobile tech-
nologies form a solid infrastructure that can be 
used via personal digital devices . Examples of 
these are laptop computers, tablet computers, 
and smart phones . Many mobile devices are capa-
ble to utilize almost all of the previously men-
tioned communication standards . Large compa-
nies are creating mobile ecosystems around these 
technologies .
Clinical laboratories can now provide comprehen-
sive information services based on mobile tech-
nology . Almost every phase of the laboratory pro-
cess from specimen collection to results reporting 
will be in the future based on mobile technology .
PL3 - How to approach malnutrition 
from laboratory point of view?
PL3 – 1
Failure to thrive in childhood and the 
laboratory
Abstract not provided .
PL3 – 2
Clinical biochemistry in nutrition practice
Alastair Forbes
UCL, London, United Kingdom
Corresponding author: a .forbes@ucl .ac .uk
Nutrition screening is of considerable value in 
identifying patients with malnutrition or at high 
risk of malnutrition, and the most successful 
screening tools rely on simple clinical tools with-
out the need for venesection or urine collection 
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(and therefore avoidany delay beyond the time of 
interview) .
Nutritional assessment is a more detailed process 
that will normally include a set of anthropometric 
measurements, and may include study of body 
composition (such as with bioelectrical imped-
ance or DEXA scanning), and indirect calorimetry 
to complement standard predictive equations 
(such as Harris-Benedict) for the determination of 
energy requirements, as well as a professional 
opinion of nutritional status . It is unusual for these 
assessments to include biochemical parameters of 
necessity, or for the conclusion to incorporate bio-
chemical data, although most patients will have 
had simple routine laboratory assays performed .
Those outside the clinical nutrition field often con-
sider that the serum albumin is a marker of malnu-
trition, but there is very little evidence in favour of 
this assumption . There is no doubt that a low albu-
min is strongly predictive of a poor outcome, and 
there is therefore a positive correlation between 
low albumin and malnutrition, but it is not now 
considered to be of a causal nature . A similar con-
clusion can be attached to many other biochemi-
cal analyses, and none of the major clinical nutri-
tion guidelines recommends their use in initial as-
sessment . In summary we might usefully conclude 
that biochemical analysis plays little role in macro-
nutrient assessment .
Nonetheless patients with malnutrition frequently 
have many biochemical deficiencies and in princi-
ple it would be good practice for clinicians to en-
sure that micronutrient status is comprehensively 
assessed . The difficulties here are that the assays 
for many micronutrients are not readily available, 
and because the interpretation of assay results is 
often neither simple nor transparent . This assess-
ment will therefore often be limited to the meas-
urement of a few key vitamins (e .g . folate, vitamins 
B12 and D) and elements (e .g . Mg, Se, Zn) and to a 
few surrogates (such as coagulation status for vita-
min K) .
Accordingly most of the interface between the 
clinical biochemist and the clinical nutritionist will 
be in management and monitoring of patients on 
artificial nutrition support and particularly those 
on parenteral nutrition (PN) . Conventional hepatic 
and renal biochemistry will generally be moni-
tored closely in the early days of PN, permitting 
adjustment and optimisation of volume and elec-
trolyte load . Deteriorating liver function is rare in 
good hands and abnormalities much more often 
reflect underlying disease such as sepsis . Correc-
tion of micronutrient deficiency will also be moni-
tored but this is not straightforward given the un-
certainties of correct intravenous replacement and 
the availability of some micronutrients only in 
composite fixed dose formats .
Special and challenging situations such as the 
management of systemic acidosis or apparently 
intractable excess or deficiency of certain electro-
lytes provide the territory for productive liaison 
between the biochemical and nutritional disci-
plines . 
